Puesta al día orientada a la clínica | 24 OCT 23

Enfermedad pulmonar obstructiva crónica

Avances recientes en la comprensión de la patogénesis y los paradigmas de tratamiento.
Autor/a: Michael C. Ferrera,WassimW. Labaki, MeiLan K. Han Annual Review of Medicine. Vol 72:119-134
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas

1. Fishman AP. 2005. One hundred years of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 171(9):941–48

2. Soriano JB, Abajobir AA, Abate KH, et al. 2017. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 5(9):691–706

3. Kochanek KD, Murphy SL, Xu J, Arias E. 2017. Mortality in the United States, 2016. NCHS Data Brief 293, National Center for Health Statistics, Hyattsville,MD

4. Fletcher C, Peto R. 1977. The natural history of chronic airflow obstruction.Br.Med. J. 1(6077):1645–48.

5. Lange P, Celli B, Agustí A, et al. 2015. Lung-function trajectories leading to chronic obstructive pulmonary disease.N. Engl. J. Med. 373(2):111–22

6. Den Dekker HT, Jaddoe VWV, Reiss IK, et al. 2018. Fetal and infant growth patterns and risk of lower lung function and asthma.Am. J. Respir. Crit.CareMed. 197(2):183–92

7. Belgrave DCM, Granell R, Turner SW, et al. 2018. Lung function trajectories from pre-school age to adulthood and their associations with early life factors: a retrospective analysis of three population-based birth cohort studies. Lancet Respir.Med. 6(7):526–34

8. Casas M, Den DekkerHT, Kruithof CJ, et al. 2018. The effect of early growth patterns and lung function on the development of childhood asthma: a population based study. Thorax 73(12):1137–45

9. Bui DS, Lodge CJ, Burgess JA, et al. 2018. Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life. Lancet Respir. Med. 6(7):535–44

10. Heijink IH, Noordhoek JA,Timens W, et al. 2014. Abnormalities in airway epithelial junction formation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 189(11):1439–42

11. Staudt MR, Buro-Auriemma LJ,WaltersMS, et al. 2014. Airway basal stem/progenitor cells have diminished capacity to regenerate airway epithelium in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 190(8):955–58

12. Burgel PR, Bourdin A, Chanez P, et al. 2011. Update on the roles of distal  airways in COPD. Eur. Respir. Rev. 20(119):7–22

13. Yang J, Zuo WL, Fukui T, et al. 2017. Smoking-dependent distal-to-proximal repatterning of the adult human small airway epithelium. Am. J. Respir. Crit. Care Med. 196(3):340–52

14. Boucher RC. 2019. Muco-obstructive lung diseases. N. Engl. J.Med. 380(20):1941–53

15. KesimerM, Ford AA, Ceppe A, et al. 2017. Airwaymucin concentration as a marker of chronic bronchitis. N. Engl. J. Med. 377(10):911–22

16. Martinez FJ, Han MK, Allinson JP, et al. 2018. At the root: defining and halting progression of early chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 197(12):1540–51

17. Hogg JC, Paré PD, Hackett TL. 2017. The contribution of small airway obstruction to the pathogenesis of chronic obstructive pulmonary disease. Physiol. Rev. 97(2):529–52

18. Hogg JC,Macklem PT, ThurlbeckWM. 1968. Site and nature of airway obstruction in chronic  obstructive lung disease.N. Engl. J. Med. 278(25):1355–60

19. McDonough JE, Yuan R, Suzuki M, et al. 2011. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease.N. Engl. J. Med. 365(17):1567–75

20. Martinez CH,Mannino DM, Jaimes FA, et al. 2015. Undiagnosed obstructive lung disease in the United States. Associated factors and long-term mortality. Ann. Am. Thorac. Soc. 12(12):1788–95

21. Han MLK,Min GK,Mardon R, et al. 2007. Spirometry utilization for COPD: How do we measure up? Chest 132(2):403–9

22. Siu AL, Bibbins-Domingo K, Grossman DC, et al. 2016. Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force recommendation statement. JAMA 315(13):1372–77 130

23. Labaki WW,HanMLK. 2018. Improving detection of early chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 15(Suppl. 4):S243–48

24. Martinez FJ,Mannino D, LeidyNK, et al. 2017.A new approach for identifying patients with undiagnosed chronic obstructive pulmonary disease.Am. J. Respir. Crit.CareMed. 195(6):748–56

25. Singh D, Agusti A, Anzueto A, et al. 2019. Global strategy for the diagnosis, management, and  prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur. Respir. J. 53(5):1900164

26. Pellegrino R, Viegi G, Brusasco V, et al. 2005. Interpretative strategies for lung function tests. Eur. Respir. J. 26(5):948–68

27. Çolak Y, Afzal S, Nordestgaard BG, et al. 2018. Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a populationbased prospective cohort study. Eur. Respir. J. 51(3):1702681

28. Bhatt SP, Balte PP, Schwartz JE, et al. 2019. Discriminative accuracy of FEV1:FVC thresholds for COPD-related hospitalization and mortality. JAMA 321(24):2438–47

29. Pauwels RA, Buist AS, Calverley PMA, et al. 2001. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.Am. J. Respir. Crit.CareMed. 163(5):1256–76

30. Rabe KF, Hurd S, Anzueto A, et al. 2007. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176(6):532–55

31. Mannino DM. 2006. GOLD stage 0 COPD: Is it real? Does it matter? Chest 130(2):309–10

32. Tan WC, Bourbeau J, Hernandez P, et al. 2014. Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study. Thorax 69(8):709– 17

33. Martinez CH, Kim V, Chen Y, et al. 2014. The clinical impact of non-obstructive chronic bronchitis in current and former smokers. Respir.Med. 108(3):491–99

34. Wijnant SRA, de Roos E, Kavousi M, et al. 2020. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam study. Eur. Respir. J. 55(1):1901217

35. Woodruff PG, Barr RG, Bleecker E, et al. 2016. Clinical significance of symptoms in smokers with preserved pulmonary function.N. Engl. J. Med. 374(19):1811–21

36. Mets OM, Buckens CFM, Zanen P, et al. 2011. Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans. JAMA 306(16):1775–81

37. Regan EA, Lynch DA, Curran-Everett D, et al. 2015. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern.Med. 175(9):1539–49

38. Galbán CJ, Han MK, Boes JL, et al. 2012. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat.Med. 18(11):1711–15

39. Bhatt SP, Soler X,Wang X, et al. 2016. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease.Am. J. Respir. Crit.CareMed. 194(2):178–84

40. Vasilescu DM, Martinez FJ, Marchetti N, et al. 2019. Noninvasive imaging biomarker identifies small airway damage in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 200(5):575–81

41. Sin DD, Vestbo J. 2009. Biomarkers in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 6(6):543–45

42. Agustí A, Edwards LD, Rennard SI, et al. 2012. Persistent systemic inflammation is associated with por clinical outcomes in COPD: a novel phenotype. PLOS ONE 7(5):e37483

43. Dahl M,Vestbo J, Lange P, et al. 2007. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease.Am. J. Respir. Crit.CareMed. 175(3):250–55

44. Butler CC, Gillespie D, White P, et al. 2019. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations.N. Engl. J. Med. 381(2):111–20

45. Mannino D, Tal-Singer R, Lomas D, et al. 2014. Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD. Chronic Obstr. Pulm. Dis. 2(1):23–34

46. Vedel-Krogh S, Nielsen SF, Lange P, et al. 2016. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: the Copenhagen General Population Study. Am. J. Respir. Crit. Care Med. 193(9):965–74

47. Pascoe S, Barnes N, Brusselle G, et al. 2019. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir.Med. 7(9):745–56

48. Yonchuk JG, Silverman EK, Bowler RP, et al. 2015. Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung. Am. J. Respir. Crit. Care Med. 192(7):785–92



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023